Lewes, DE -- (SBWIRE) -- 11/01/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Jive Software Inc (NASDAQ:JIVE), Array Biopharma Inc (NASDAQ:ARRY), Rovi Corporation (NASDAQ:ROVI), Idera Pharmaceuticals Inc (NASDAQ:IDRA).
Jive Software Inc (NASDAQ:JIVE), decreased -14.19% and closed at $10.91 on a traded volume of 3.92 million shares, in comparison to 664,216 shares of average trading volume. So far this year, the stock is down over-24.88%.
The company has a total market capitalization of $750.53 million and its total outstanding shares are 68.76 million.
Will JIVE Get Buyers Even After The Recent Rally? Find Out Here
Jive Software, Inc. provides a social business software platform to businesses, government agencies, and other enterprises. Its flagship product, the Jive Platform, offers social business capabilities that enable employee, customer, and partner engagement on a unified platform.
Array Biopharma Inc (NASDAQ:ARRY), plunged -4.10% and closed at $5.03 on a traded volume of 3.88 million shares, whereas its average trading volume is 1.88 million shares. In the last three months, the stock is down -7.27%. The Intra-day range for the stock is $4.83 and $5.47.
Has ARRY Found The Bottom and Ready To Move Up? Find Out Here
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific.
Rovi Corporation (NASDAQ:ROVI), dropped down -11.68% and closed at $16.75. So far in three months, the stock is down -13.77%. The 52-week range for the stock is $13.25 and $26.55 and during the previous trading session it marked$17.91 as its highest price. The stock initially exchanged hands with a price of $17.74 and the overall traded volume that day was 3.83 million shares.
Has ROVI Found The Bottom And Ready To Gain Momentum? Find Out Here
Rovi Corporation provides integrated solutions that enable the discovery, delivery, display, and monetization of digital entertainment.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) after opening its shares at the price of $2.10, dropped -14.02% to close the day at $1.84. The stock ended on a traded volume of 3.82 million shares, in comparison to 1.90 million shares of average trading volume. The 52-week range for the stock is $0.19 and $3.12and during the previous trading session the stock scored the highest price of $2.14. It started the day at $2.10.
Will IDRA Get Buyers Even After The Recent Rally? Find Out Here
Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates.
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/